HKSE:02410 has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
HKSE:02410 has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
TYK Medicines's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was HK$111.54 Mil. TYK Medicines's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was HK$18.41 Mil. TYK Medicines's Total Stockholders Equity for the quarter that ended in Jun. 2024 was HK$-1,126.60 Mil. TYK Medicines's debt to equity for the quarter that ended in Jun. 2024 was -0.12.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for TYK Medicines's Debt-to-Equity or its related term are showing as below:
During the past 2 years, the highest Debt-to-Equity Ratio of TYK Medicines was -0.05. The lowest was -0.13. And the median was -0.11.
The historical data trend for TYK Medicines's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TYK Medicines Annual Data | |||||
Trend | Dec22 | Dec23 | |||
Debt-to-Equity | -0.11 | -0.05 |
TYK Medicines Quarterly Data | ||||||||
Dec22 | Mar23 | Jun23 | Dec23 | Mar24 | Jun24 | |||
Debt-to-Equity | Get a 7-Day Free Trial | N/A | N/A | -0.05 | -0.13 | -0.12 |
For the Biotechnology subindustry, TYK Medicines's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, TYK Medicines's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where TYK Medicines's Debt-to-Equity falls into.
Debt to Equity measures the financial leverage a company has.
TYK Medicines's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as
Debt to Equity | = | Total Debt | / | Total Stockholders Equity | ||
= | (Short-Term Debt & Capital Lease Obligation | + | Long-Term Debt & Capital Lease Obligation) | / | Total Stockholders Equity | |
= | (24.31 | + | 21.332) | / | -967.426 | |
= | -0.05 |
TYK Medicines's Debt to Equity Ratio for the quarter that ended in Jun. 2024 is calculated as
Debt to Equity | = | Total Debt | / | Total Stockholders Equity | ||
= | (Short-Term Debt & Capital Lease Obligation | + | Long-Term Debt & Capital Lease Obligation) | / | Total Stockholders Equity | |
= | (111.544 | + | 18.414) | / | -1126.601 | |
= | -0.12 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TYK Medicines (HKSE:02410) Debt-to-Equity Explanation
In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.
Be Aware
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Thank you for viewing the detailed overview of TYK Medicines's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.
Nan Jing Yi Da Tou Zi Guan Li You Xian Gong Si | ||
Nan Jing Yi Da Zi Ben Guan Li Qi Ye You Xian He Huo | ||
Jiang Su Yi Da Gu Quan Tou Zi Ji Jin Guan Li You Xian Gong Si | ||
Wu Yusheng | 2201 Interest of corporation controlled by you | |
Zhu Julia Ming | 2202 Interest of your spouse | |
Zheng Zhou Tai Ji Hong Nuo Yi Yao Gu Fen You Xian Gong Si | 2101 Beneficial owner | |
Zhang Xing Li Yuan Qi Ye Guan Li He Huo Qi Ye You Xian He Huo | 2101 Beneficial owner | |
He Chao | 2201 Interest of corporation controlled by you | |
Bei Jing Hou Ji Jing Qiao Chuang Ye Tou Zi You Xian Gong Si | 2201 Interest of corporation controlled by you | |
Bei Jing Rong Chen Hou Ji Tou Zi Guan Li You Xian Gong Si | 2201 Interest of corporation controlled by you | |
Zhang Xing Xing Zhang Chan Ye Tou Zi He Huo Qi Ye You Xian He Huo | 2101 Beneficial owner |
No Headlines
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.